SCHEMBL206648

SCHEMBL206648

CCOC(=O)C(C)NC(=O)CCC(=O)NC1CCC(Cc2cccc(Cl)c2)(N(C)C)CC1

nearest known ligand 0.42

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
EPHX2 P34913 1/20 0.42
HPGD P15428 2/20 0.42
THRB P10828 1/20 0.42
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
LMNA P02545 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
NPC1 O15118 1/20 0.39
SIGMAR1 Q99720 2/20 0.39
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4081016 0.89 EPHX2 (0.45) ALDH1A1EPHX2HPGDTHRBL3MBTL1
SCHEMBL207560 0.89 POLB (0.41) ALDH1A1HPGDMEN1KMT2ALMNA
SCHEMBL206443 0.84 EPHX2 (0.42) ALDH1A1EPHX2HPGDTHRBMEN1
SCHEMBL206966 0.83 EPHX2 (0.62) EPHX2HPGDTHRBMEN1KMT2A
SCHEMBL205753 0.83 SIGMAR1 (0.45) EPHX2HPGDTHRBSIGMAR1
SCHEMBL207761 0.83 ALDH1A1 (0.51) ALDH1A1MEN1KMT2ALMNAL3MBTL1
SCHEMBL206650 0.82 KMT2A (0.44) ALDH1A1EPHX2HPGDTHRBMEN1
SCHEMBL206577 0.82 SIGMAR1 (0.43) EPHX2HPGDTHRBKMT2ANPC1
SCHEMBL207872 0.82 SIGMAR1 (0.46) ALDH1A1EPHX2HPGDTHRBMEN1
SCHEMBL205864 0.81 POLB (0.43) ALDH1A1EPHX2HPGDTHRBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD ALDH1A1 158/4885EPHX2 1203/4885HPGD 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.